Cover Image
市場調查報告書

萬古霉素抗藥性腸球菌感染疾病:開發中產品分析

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 264091
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
萬古霉素抗藥性腸球菌感染疾病:開發中產品分析 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 85 Pages
簡介

萬古黴素抗藥性腸球菌的病原性株被稱為VRE,是院內感染的主因。症狀依感染部位不同而異。細菌一般是透過腸道、傷口、尿道感染。傷口感染的情況會產生感染部位發紅、壓痛、腫起。尿道感染的情況下會有背部疼痛、排尿時產生灼熱感。其他常見的症狀還有噁心、發熱、發冷、激烈頭痛、腹瀉等。要預防感染,有效實行衛生管理是不可或缺的。

本報告提供萬古霉素抗藥性腸球菌感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

萬古霉素抗藥性腸球菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alchemia Ltd
  • Aphios Corp
  • C3J Therapeutics Inc
  • Helix BioMedix Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Ovensa Inc
  • Sealife PHARMA GMBH
  • Wockhardt Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10419IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2018, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 4
  • Vancomycin-Resistant Enterococcus faecium Infections - Overview 5
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development 6
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 15
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 23
  • Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles 30
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 74
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 77
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 78
  • Appendix 81

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2018 9
  • Number of Products under Development by Companies, H1 2018 11
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 12
  • Number of Products under Development by Universities/Institutes, H1 2018 13
  • Products under Development by Companies, H1 2018 14
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018 16
  • Products under Development by Universities/Institutes, H1 2018 17
  • Number of Products by Stage and Target, H1 2018 19
  • Number of Products by Stage and Mechanism of Action, H1 2018 21
  • Number of Products by Stage and Route of Administration, H1 2018 23
  • Number of Products by Stage and Molecule Type, H1 2018 25
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Ltd, H1 2018 26
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H1 2018 26
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AzurRx BioPharma Inc, H1 2018 27
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3J Therapeutics Inc, H1 2018 27
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018 28
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ferring International Center SA, H1 2018 28
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H1 2018 28
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018 29
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, H1 2018 29
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H1 2018 30
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2018 30
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H1 2018 31
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H1 2018 31
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2018 31
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H1 2018 32
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2018 77
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018 79
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2018 80

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2018 9
  • Number of Products under Development by Companies, H1 2018 10
  • Number of Products under Development by Universities/Institutes, H1 2018 13
  • Number of Products by Top 10 Targets, H1 2018 18
  • Number of Products by Stage and Top 10 Targets, H1 2018 18
  • Number of Products by Top 10 Mechanism of Actions, H1 2018 20
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 20
  • Number of Products by Routes of Administration, H1 2018 22
  • Number of Products by Stage and Routes of Administration, H1 2018 22
  • Number of Products by Molecule Types, H1 2018 24
  • Number of Products by Stage and Molecule Types, H1 2018 24
Back to Top